Nanoparticles for the treatment of liver fibrosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Chronic liver diseases represent a global health problem due to their high prevalence worldwide and the limited available curative treatment options. They can result from various causes, both infectious and noninfectious diseases. The application of nanoparticle (NP) systems has emerged as a rapidly evolving area of interest for the safe delivery of various drugs and nucleic acids for chronic liver diseases. This review presents the pathogenesis, diagnosis and the emerging nanoparticulate systems used in the treatment of chronic liver diseases caused by liver fibrosis. Activated hepatic stellate cell (HSC) is considered to be the main mechanism for liver fibrosis. Ultrasonography and magnetic resonance imaging techniques are widely used noninvasive diagnostic methods for hepatic fibrosis. A variety of nanoparticulate systems are mainly focused on targeting HSC in the treatment of hepatic fibrosis. As early liver fibrosis is reversible by current NP therapy, it is being studied in preclinical as well as clinical trials. Among various nanoparticulate systems, inorganic NPs, liposomes and nanomicelles have been widely studied due to their distinct properties to deliver drugs as well as other therapeutic moieties. Liposomal NPs in clinical trials is considered to be a milestone in the treatment of hepatic fibrosis. Currently, NP therapy for liver fibrosis is updating fast, and hopefully, it can be the future remedy for liver fibrosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
A Review of Clinical Translation of Inorganic Nanoparticles
Anselmo, A. C., & Mitragotri, S. (2015) · The AAPS Journal · doi:10.1208/s12248-015-9780-2 · Cited by 509
Baeck, C., Wei, X., Bartneck, M., Fech, V., Heymann, F., Gassler, N., Hittatiya, K., Eulberg, D., Luedde, T., Trautwein, C., et al. (2014) · Hepatology · doi:10.1002/hep.26783 · Cited by 270
Bartneck, M., Scheyda, K. M., Warzecha, K. T., Rizzo, L. Y., Hittatiya, K., Luedde, T., Storm, G., Trautwein, C., Lammers, T., & Tacke, F. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.10.030 · Cited by 141
Targeting dexamethasone to Kupffer cells: Effects on liver inflammation and fibrosis in rats
Melgert, B. N., Olinga, P., Van Der Laan, J. M. S., Weert, B., Cho, J., Schuppan, D., Groothuis, G. M. M., Meijer, D. K. F., & Poelstra, K. (2001) · Hepatology · doi:10.1053/jhep.2001.27805 · Cited by 115 · cited 1×
“Both in vitro and in vivo studies in bile duct-ligated mice showed that the NP effectively inhibited tumor necrosis factor (TNF-α) in vitro and reduced intrahepatic ROS in vivo.(62) HSAs modified with M6P NPs with a particle size of 280 nm have been used for targeting TGFβ fibrogenic cytokine through the M6P/IG II rec…”
Cited by
Beneficial effects of naringenin in liver diseases: Molecular mechanisms
Hernández-Aquino, E., & Muriel, P. (2018) · World Journal of Gastroenterology · doi:10.3748/wjg.v24.i16.1679 · Cited by 347
Liver fibrosis resolution: from molecular mechanisms to therapeutic opportunities
Pei, Q., Yi, Q., & Tang, L. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119671 · Cited by 121
It’s all about the spaces between cells: role of extracellular matrix in liver fibrosis
Khurana, A., Sayed, N., Allawadhi, P., & Weiskirchen, R. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-2948 · Cited by 79
Mesenchymal stromal cells: promising treatment for liver cirrhosis
Yao, L., Hu, X., Dai, K., Yuan, M., Liu, P., Zhang, Q., & Jiang, Y. (2022) · Stem Cell Research & Therapy · doi:10.1186/s13287-022-03001-z · Cited by 71
The Role of Macrophages in Liver Fibrosis: New Therapeutic Opportunities
Binatti, E., Gerussi, A., Barisani, D., & Invernizzi, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126649 · Cited by 62
“(For a complete overview of the advances in the research of nanocarriers for targeted treatments of liver fibrosis, see references [57,82]).”
Background
Metadata
- Authors
- Poilil Surendran, S., George Thomas, R., Moon, M.-J., & Jeong, Y. Y.
- Venue
- International Journal of Nanomedicine
- Publisher
- Informa UK Limited
- Published
- 2017-09
- Volume
- Volume 12
- Pages
- 6997-7006
- ISSN
- 1176-9114 (ISSN-L)
- 1178-2013
- OpenAlex
- W2755540671
- Cited by
- 139
- References
- 5
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Nanoparticles for the treatment of liver fibrosis. https://app.cochat.ai/papers/10.2147/ijn.s145951
- The paper
- Poilil Surendran, S., George Thomas, R., Moon, M.-J., & Jeong, Y. Y. (2017). Nanoparticles for the treatment of liver fibrosis. International Journal of Nanomedicine. https://doi.org/10.2147/ijn.s145951
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.